SCHEMBL2429207

SCHEMBL2429207

CCOC(=O)c1ccc(OC(C(=O)OC(C)(C)C)N2CCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
RAB9A P51151 4/20 0.44
ALDH1A1 P00352 3/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 2/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ESR1 P03372 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
ESR2 Q92731 1/20 0.41
CA14 Q9ULX7 1/20 0.41
STS P08842 1/20 0.41
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72448 0.80 KCNH2 (0.51) KCNH2HRH3RAB9AALDH1A1NPC1
SCHEMBL3580271 0.78 KCNH2 (0.49) KCNH2HRH3RAB9AALDH1A1NPC1
SCHEMBL7476501 0.75 CHRNB2 (0.38) KCNH2HRH3RAB9ANPC1SMN1; SMN2
Oxalic Acid SCHEMBL3579470 0.75 KCNH2 (0.46) KCNH2HRH3RAB9AALDH1A1NPC1
SCHEMBL7398728 0.74 MEN1 (0.45) KCNH2HRH3RAB9AALDH1A1NPC1
SCHEMBL18608207 0.73 CA1 (0.63) RAB9AALDH1A1NPC1SMN1; SMN2HPGD
SCHEMBL7411612 0.72 CHRNB2 (0.41) GAA
SCHEMBL7413845 0.71 KMT2A (0.40) HRH3RAB9ALMNAGAAL3MBTL1
SCHEMBL31664440 0.70 CA12 (0.56) RAB9AALDH1A1SMN1; SMN2HPGDCA12
SCHEMBL2302426 0.70 HPGD (0.54) RAB9AALDH1A1SMN1; SMN2HPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 KCNH2 1176/4885HRH3 130/4885RAB9A 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.